Part 2/10:
Interestingly, Americans can access stem cell treatments abroad but face regulatory hurdles domestically. Dr. Hariri explains that the United States is cautious, often delaying the approval of these therapies due to stringent regulations by the FDA. Despite significant advancements and decades of research indicating the safety and efficacy of stem cell treatments—such as established procedures involving bone marrow transplants—progress remains slow.
Today's patients often travel to countries like Panama, Costa Rica, and Mexico seeking treatments that are not yet approved in the U.S. This highlights a gap between available technology and regulatory actions, creating a sense of urgency in the discussion around making these treatments more accessible domestically.